Recipharm, the global contract development and manufacturing organisation (CDMO), has announced its commitment to helping victims of the conflict in Ukraine. The company is taking steps to provide support to those of its own employees who are directly impacted and to launch a fundraising campaign in which it will match the financial contributions of its staff.

CEO Marc Funk said: 'Given the unprovoked invasion of Ukraine and the tragic humanitarian crisis which is now unfolding, we believe it is important to offer our help wherever it can be most effective. We at Recipharm are working with NGO partners to provide urgent aid and other humanitarian assistance to refugees. Our employees are keen to engage with this issue and to lend their support where they can, so we are setting up a matched funding arrangement to facilitate the donation process, working in conjunction with UNICEF, our chosen partner.'

Contact:

Marcus Smith

Head

Communications

Recipharm

E: marcus.smith@recipharm.com

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

Contact:

Recipharm AB

Corporate identity number: 556498-8425

Address Box 603

SE-101 32 Stockholm

Sweden

Telephone: +46 8 602 52 00

WEB: www.recipharm.com

(C) 2022 Electronic News Publishing, source ENP Newswire